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P.C. Sanelli, S. Kishore, A. Gupta, H. Mangat, A. Rosengart, H. Kamel, and A. Segal
Departments of Radiology, Division of Neuroradiology (P.C.S., S.K., A.G.); Public Health (P.C.S.); 
and Neurology, Division of Stroke and Critical Care (H.M., A.R., H.K., A.S.), NewYork-
Presbyterian Hospital�Weill Cornell Campus, New York, New York.
Abstract
SUMMARY: Aneurysmal subarachnoid hemorrhage is associated with high morbidity and 
mortality, with delayed neurologic deficits from delayed cerebral ischemia contributing to a large 
portion of the adverse outcomes in this patient population. There is currently no consensus 
reference standard for establishing the diagnosis of delayed cerebral ischemia either in the 
research or clinical settings, ultimately limiting strategies for preventing delayed infarction and 
permanent neurologic deficits. There are currently both clinical and imaging-based criteria for the 
diagnosis of delayed neurologic deficits and vasospasm, respectively, however, neither clinical nor 
angiographic assessment alone has been shown to identify patients who develop adverse outcomes 
from delayed infarction. Thus, the purpose of this work is to propose a 3-tiered combined imaging 
and clinical reference standard based on evidence from the literature to standardize the diagnosis 
of delayed cerebral ischemia, both to allow consistency across research studies and to ultimately 
improve outcomes in the clinical setting.
A neurysmal subarachnoid hemorrhage (aSAH) is associated with high morbidity and 
mortality.1,2 The first 2 weeks following aSAH are critical in the management of these 
patients because they are prone to develop several life-threatening complications, including 
delayed neurologic deficits,3 which often arise from delayed cerebral ischemia (DCI), a 
major contributor to the adverse outcomes in this population.3–5 Delayed cerebral ischemia 
manifests in approximately 30% of patients with aSAH and typically occurs between days 4 
and 9 after the initial hemorrhage, though it can range from 3 to 14 days.
There remains a lack of standard criteria for defining DCI in the clinical setting,3,6,7 with a 
recent literature review describing at least 8 terms to define the concept of DCI in aSAH.6 
Debate over the role of clinical and imaging assessments in defining DCI has occurred for 
both clinical and research purposes.3,6,8–10 For example, although the terms “DCI” and 
“vasospasm” have been used interchangeably, attempts have been made to distinguish DCI 
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from vasospasm, with the former often determined clinically, and the latter, 
radiographically,6 because not all patients with clinical neurologic deficits have 
angiographic vasospasm and not all patients with angiographic vasospasm have neurologic 
deficits that correspond to the arterial territory of vasospasm.11,12 Additionally, while severe 
vasospasm may cause decreased cerebral perfusion, a substantial percentage of patients 
develop infarction without evidence of vasospasm, suggesting that DCI should be defined as 
a pathologic process, of which vasospasm may represent a contributing factor.12,13
Thus, the aim of this article is to propose an evidence-based reference standard for DCI that 
incorporates both clinical assessments of neurologic deterioration and imaging assessments 
of vasospasm, perfusion deficits, and infarction to provide a consistent, uniform standard 
across a wide range of clinical and research applications. The classification of levels of 
evidence supporting this reference standard is based on the Levels of Evidence criteria 
proposed by the Oxford Centre of Evidence Based Medicine (www.cebm.net).14 Two 
independent reviewers assessed levels of evidence for each tier, and in the case of 
discordance, evidence level assignments were made by consensus.
DESCRIPTION OF THE COMBINED CLINICAL AND IMAGING REFERENCE 
STANDARD
(Algorithm displayed in Fig 1)
Primary Level: Outcome-Based Criteria
Summary—The primary level classifies patients as having DCI if a new infarction on 
imaging or new permanent neurologic deficit develops. A new infarction on imaging is 
determined on CT or MR imaging within 6 weeks after aSAH ictus that was not present on 
imaging up to 48 hours after aneurysm occlusion and was not attributable to other causes 
such as surgical clipping, endovascular treatment, ventricular catheter placement, 
intraparenchymal hematoma, or cerebral herniation. A new permanent neurologic deficit is 
determined on clinical examination as a new neurologic deficit distinct from the baseline 
examination performed immediately after aneurysm rupture or aneurysm occlusion and not 
attributable to other causes. Baseline neurologic examination must be considered after full 
cardiorespiratory, hemodynamic, and metabolic resuscitation as well as treatment of other 
factors such as seizures and hydrocephalus. Patients who do not meet either criterion are 
referred to the secondary level, as described in a subsequent section.
Evidence: Level 1A evidence exists to support these proposed outcomes-based criteria for 
determining DCI.
An ideal reference standard should reliably identify patients with a high risk of poor 
outcomes who may benefit from intervention. In large prospective cohort studies, the 
greatest predictors of severe disability or death at 3 months were a new focal neurologic 
deficit, a new infarction on follow-up imaging, or both.6,15,16 Additionally, a large 
systematic review and meta-analysis of all randomized placebo-controlled trials evaluating 
the efficacy of protective strategies in aSAH concluded that a reduced incidence of cerebral 
infarction is significantly associated with improved functional outcome.17 In fact, new 
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cerebral infarction alone was as strongly correlated with poor 3-month functional outcome 
as the combination of a new neurologic deficit and corresponding ischemic changes on 
follow-up neuroimaging.6 Furthermore, cerebral infarction on noncontrast CT was the 
primary outcome measure in the early trials of nimodipine, an agent with strong evidence for 
neuroprotection of DCI.18
While angiographic vasospasm has traditionally been the primary focus of interventions and 
prediction of outcomes, the lack of evidence demonstrating improved outcomes with 
vasospasm prevention13,19 has led to incorporating this criterion combined with clinical 
correlation in the secondary level below.
Secondary Level: Correlation of Clinical and Vascular Imaging Criteria
Summary—The secondary level classifies patients as having DCI if both clinical 
deterioration and angiographic vasospasm occur. Clinical deterioration is determined by 
bedside examination and comprises the development of a new neurologic deficit (such as 
hemiparesis, hemiplegia, aphasia, depressed consciousness, and so forth), a decrease of at 
least 2 points on the Glasgow Coma Scale, or a decrease of at least 1 point in the motor 
score, lasting >1 hour at any point after aneurysm occlusion and not attributable to other 
causes. Vascular imaging for the evaluation of vasospasm includes imaging modalities, such 
as transcranial Doppler sonography, CTA, MRA, and DSA. Patients with neurologic 
deterioration and 1 imaging test supporting a diagnosis of vasospasm are classified as having 
DCI. On the other hand, patients without neurologic deterioration and 1 imaging test without 
findings of vasospasm are classified as not having DCI. However, patients with either 
positive clinical or imaging findings that do not correlate with each other are referred to the 
tertiary level, as described in a subsequent section.
Evidence: Level 1B evidence exists to support using clinical and vascular imaging data for 
determining DCI.
Evaluation of patients for DCI at the secondary level is most valuable in the clinical setting 
at the point of care when treatment decisions are made. The primary goal of treatment is to 
prevent cerebral infarction and permanent neurologic deficits. Thus, traditionally, imaging 
assessment of vasospasm has been used as a surrogate marker to assist in the diagnosis of 
DCI, especially given that neurologic deterioration is poorly evaluated in sedated or 
obtunded patients. Angiographic vasospasm, seen on DSA or CTA, is perhaps the most 
commonly used surrogate imaging marker in this patient population. Vasospasm has been 
shown to be strongly associated with DCI, cerebral infarction, poor outcome, and increased 
mortality within several retrospective and prospective cohort studies, including a post hoc 
analysis of data from the CONSCIOUS (Clazosentan to Overcome Neurological Ischemia 
and Infarct Occurring after Subarachnoid Hemorrhage)- 1 trial.11,20–23 However, an analysis 
of data from 2 systematic reviews and a post hoc analysis did not demonstrate an 
improvement in outcome with a reduction in angiographic vasospasm.19 Evidence from both 
prospective and retrospective cohort studies suggests that patients with angiographic 
vasospasm and correlated symptoms have worse hospital complications and subsequent 
disability compared with angiographic vasospasm alone.9,16 However, there is less evidence 
to demonstrate the prognostic importance of angiographic vasospasm correlated with 
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symptoms, thus placing this criterion at the secondary level. Although relatively inferior in 
terms of sensitivity and specificity, transcranial Doppler sonography evaluations of the 
intracranial vessels can also be performed at bedside to identify arterial narrowing in 
patients who may be too unstable for more advanced angiographic techniques such as CTA, 
MRA, or DSA.24,25
Tertiary Level: Correlation of Physiologic Data with Clinical or Imaging Criteria
Summary—The tertiary level classifies patients as having DCI if physiologic data 
correlates with either clinical deterioration or vasospasm. Patients with either clinical 
deterioration or vasospasm alone may undergo additional physiologic assessment of cerebral 
hemodynamics, either in the form of imaging such as CTP and MR perfusion (MRP) or 
neuromonitoring devices such as cerebral blood flow, oxygen tension monitoring, and 
cerebral microdialysis. Patients with findings suggestive of regional cerebral hypoperfusion 
or hypoxia that correlate with either clinical deterioration or vasospasm are classified as 
having DCI. Patients with clinical deterioration or vasospasm but normal physiologic data 
do not have sufficient evidence to be classified as having DCI.
Evidence: Levels of evidence to support using physiologic data for determining DCI range 
from 2A to 3B, depending on the technique.
While there is at least moderate evidence supporting the importance of symptomatic 
vasospasm in DCI at the secondary level, the importance of isolated image-based diagnoses 
of vasospasm in the absence of clinical findings is somewhat controversial, especially in the 
absence of infarction. However, a subset of patients with asymptomatic vasospasm will 
develop asymptomatic ischemia and subsequent infarction. A large prospective cohort 
identified asymptomatic infarction in approximately 20% of patients with aSAH, and 
furthermore, these patients had a higher frequency of death and moderate-to-severe 
disability at 3 months relative to patients with symptomatic infarction.26 Thus, there may be 
a subset of patients with apparently asymptomatic vasospasm who are at high risk of 
eventually developing clinical evidence of DCI, especially those who are comatose or have a 
ventriculostomy catheter, small-volume aSAH, or ischemia in noneloquent brain26,27—all 
representing complicating factors that are not infrequently encountered in the intensive care 
setting. Identifying this high-risk subset of patients with asymptomatic vasospasm may 
prompt measures to implement therapies to prevent the eventual development of DCI.
Conversely, the identification of patients with DCI and clinical deterioration in the absence 
of vasospasm poses a different important diagnostic challenge. While neurologic 
deterioration is likely multifactorial in these patients, a subset will go on to develop 
infarction without vasospasm. A retrospective study of infarction patterns in patients with 
aSAH found that approximately 17% of patients developed infarcts without imaging 
evidence of vasospasm, and even in patients with imaging positive for vasospasm, infarcts 
also developed in areas away from the vasospastic territories.28 Thus, this level in the 
algorithm would attempt to identify ischemia in patients with asymptomatic vasospasm or 
neurologic deterioration without evidence of large-vessel vasospasm.
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Perfusion imaging such as CTP and MRP or less common modalities such as xenon-CT 
provide physiologic imaging assessments of cerebral hypoperfusion and ischemia that could 
identify patients at risk for infarction. In a retrospective cohort of 96 patients with aSAH, 
new CTP deficits seen as prolonged MTT and reduced CBF were significantly associated 
with subsequent infarction and permanent neurologic deficits.29 A smaller prospective study 
evaluating the test characteristics of CTP, CTA, and noncontrast CT obtained at baseline and 
after the onset of clinical deterioration determined that CTP had the best test performance 
for the subsequent diagnosis of DCI at discharge.30 Subsequently, systematic reviews 
evaluating CTP in aSAH within the broader context of diagnosing vasospasm and DCI 
found that relative CBF and MTT values correlated highly with subsequent DCI.25,31 Thus, 
there is level 2A evidence to support the role of CTP in the diagnosis of DCI.
Evidence to support the use of other imaging modalities to evaluate DCI is more limited. 
There are limited data evaluating the role of MRP in DCI; however, several small 
prospective cohort studies demonstrated that CTP, particularly CBF, correlates with MRP-
derived values in the same patients within a close time interval, suggesting that MR imaging 
could also be used in this setting in case CTP is not performed.32,33 The data for the use of 
xenon-CT in DCI are even more limited; however, a small prospective cohort study in 
patients with poor-grade aSAH found that CBF reduction on xenon-CT was only moderately 
predictive of infarction in these patients and that not all reductions in CBF by this technique 
resulted in infarction.34 Thus, there is at best level 2B and 3B evidence for MRP and xenon-
CT, respectively, for the diagnosis of ischemia in patients with aSAH. However, these 
imaging modalities are challenging to perform in this patient population due to scanner 
accessibility and patient contraindications.
Not all patients with aSAH undergo imaging to assess ischemia, particularly those who are 
unstable or have poor-grade conditions. Thus, noninvasive and invasive bedside monitoring 
devices such as cerebral microdialysis, brain tissue oxygenation monitoring (eg, the Licox 
system, Integra LifeSciences, Plainsboro, New Jersey), and other similar devices have been 
used to stratify patients at risk of ischemia. A systemic review evaluating the use of 
microdialysis in the assessment of cerebral ischemia in patients with aSAH found that while 
the use of the technology is increasing, there is substantial study heterogeneity, thereby 
limiting the evidence to support its utility.35 Nonetheless, a small prospective cohort of 44 
patients found that a 2-fold increase in ischemia- related metabolites from baseline at the 
time of acute neurologic deterioration was significantly associated with subsequent 
infarction and permanent neurologic deficits.36 Data for cerebral tissue oxygen monitoring 
are more limited, particularly in patients with aSAH. Several small prospective cohort 
studies demonstrated the potential utility of detecting hypoxia in aSAH by using tissue 
oxygenation monitoring.37–39 Thus, there is level 3A evidence in support of cerebral 
microdialysis and level 3B evidence to support cerebral oxygen monitoring in patients with 
aSAH.
Strengths and Limitations of Each Level
Primary Level—The main strength of the primary level is its strong evidence using 
outcome-based criteria supported by systematic reviews and large observational cohort 
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studies.3,15,17,19 Thus, the primary level captures patients with the highest mortality and 
morbidity associated with DCI. Most important, this level emphasizes specificity over 
sensitivity to accurately identify patients with DCI for treatment decisions. Additionally, 
patients with DCI who do not develop infarction or neurologic deficits cannot be 
misclassified at this level because these patients advance to the secondary level for further 
evaluation. Another strength at this level is the reproducibility in assessing patients with 
these well defined outcome measures that are less prone to inter observer variability.
The main limitation at the primary level is the reduced applicability in guiding treatment 
decisions. In clinical practice, the goal of managing patients with aSAH is to avoid these 
devastating outcomes of infarction and functional disability. At this level, patients are 
classified as having DCI according to these criteria, thus limiting improvement in patient 
outcomes with treatment.
Secondary Level—The main strength of the secondary level is the combination of new 
neurologic deficits with imaging findings suggestive of angiographic vasospasm that have 
been shown to correlate with functionally relevant outcomes.9 Because these criteria can, in 
some cases, be evaluated before development of infarction and functional disability (ie, at a 
stage in which impending DCI is still preventable), classification of patients with DCI at this 
level should theoretically provide maximal benefit from treatment. The combination of both 
new neurologic deficits and evidence of angiographic vasospasm improves the specificity 
for identifying patients with DCI, given that neurologic assessment in patients with aSAH 
can be challenging and angiographic vasospasm does not necessarily correlate with DCI.
A limitation of the secondary level is that patients without new neurologic deficits and 
without angiographic vasospasm can be misclassified as having no DCI. Comatose or 
heavily sedated patients have limited clinical assessment and may have suboptimal imaging, 
resulting in false-negatives for DCI. Although the agreement of clinical and imaging 
findings improves the specificity for identifying patients with DCI for treatment, the 
sensitivity may not be optimized at this level for a subset of patients. The probability of 
correlation is dependent on the quality of each respective evaluation, and both the clinical 
and imaging assessments at this level are subject to inter observer variability.10,40,41
Tertiary Level—The main strength of the tertiary level is improving the sensitivity of the 
DCI diagnosis by further evaluating discordant clinical and imaging findings from the 
secondary level, such as in patients with asymptomatic vasospasm or neurologic decline 
without angiographic vasospasm. Most important, this level allows further evaluation of 
comatose patients with suboptimal clinical assessments who have angiographic vasospasm 
as well as symptomatic patients who have suboptimal imaging. These patients often have 
worse outcomes in comparison with patients with symptomatic DCI, possibly related to 
delayed treatment. 26 At this level, all patients undergo physiologic assessment of cerebral 
perfusion and hypoxia to correlate with either clinical or imaging findings suggesting DCI. 
Thus, this level will include patients who may have been excluded from the diagnosis due to 
lack of sufficient evidence at the other 2 levels.
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A potential limitation of the tertiary level is that the breadth of modalities used to assess 
ischemia—ranging from noninvasive imaging to invasive tissue monitoring—has variable 
strength of evidence to support their use. From an imaging standpoint, CTP has the strongest 
evidence to support its use in diagnosing DCI; clinically, cerebral microdialysis has some 
evidence to support its use despite inconclusive results from a systematic review of the 
literature. There is limited evidence to support the use of the remaining modalities in 
diagnosing DCI in patients with aSAH.
Future Directions
While there is no perfect reference standard for this complex disease process, this 
multitiered algorithm attempts to capture the complexity of clinical and imaging findings in 
DCI according to evidence-based criteria. Specificity is emphasized in this multitiered 
reference standard with respect to evidence-based clinically relevant outcomes at the 
primary level, which are particularly valuable in the research setting to potentially improve 
translation of research findings into clinical practice. Most important, this reference standard 
approach also incorporates levels of evidence with greater sensitivity for use in clinical 
settings. The model is heavily weighted toward criteria with supportive statistical evidence 
and, through a multitiered algorithm, aims to limit the heterogeneity and controversy in 
defining DCI for research and, potentially, clinical application, combining both imaging and 
clinical assessments in the determination of DCI. The future direction for validation of this 
proposed reference standard through prospective studies may help to move forward both 
clinical care and research in this field.
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Proposed multitiered reference standard in DCI. Three-tiered DCI reference standard 
algorithm, ordered from top to bottom. Asterisk indicates neuromonitoring devices such as 
cerebral microdialysis and oximetry. Double asterisks indicate whether the reference 
standard is used for clinical assessment and treatment decisions based on the risk/benefit 
ratio for treatment. If there is low risk, treatment for DCI is recommended. If there is high 
risk, the patient should re-enter the algorithm.
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